Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells-Reference-Cited by-同舟云学术

Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells

Published:2019-03-07 Issue:5 Volume:4 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Simon Nathan,Antignani Antonella,Hewitt Stephen M.^ORCID,Gadina Massimo,Alewine Christine^ORCID,FitzGerald David

Funder

Intramural Research Program of the NIH, Center for Cancer Research, National Cancer Institute and by the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/123281/files/pdf

Reference89 articles.

1. Macrophage Regulation of Tumor Responses to Anticancer Therapies

2. Macrophages and therapeutic resistance in cancer;Ruffell;Cancer Cell,2015

3. Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

4. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors;Kumar;Cancer Cell,2017

5. Neutrophils in cancer: neutral no more

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Loss of tumor suppressors promotes inflammatory tumor microenvironment and enhances LAG3+T cell mediated immune suppression;Nature Communications;2024-07-12

2. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma;Science;2024-06-21

3. Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers;Frontiers in Oncology;2024-04-19

4. Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials;Clinical and Experimental Gastroenterology;2024-04